In Merger Plot Twist, BMS Needs A Buyer For Celgene's Otezla, Raising New Questions

 
• By Jessica Merrill

Bristol-Myers will have to divest Celgene's blockbuster psoriasis pill to address concerns raised by the US FTC related to the merger. The news raised questions about whether FTC is giving more scrutiny to pipeline overlap.

Top view of a woman reading a book. - Image
A new chapter unfolds in the Bristol/Celgene merger • Source: Shutterstock

More from Deals

More from Business